Literature DB >> 24213765

Making the biotech IPO work.

Laura McNamee1, Fred Ledley.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24213765     DOI： 10.1038/nbt.2711

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  5 in total

Review 1.  The discovery of receptor tyrosine kinases: targets for cancer therapy.

Authors:  Andreas Gschwind; Oliver M Fischer; Axel Ullrich
Journal:  Nat Rev Cancer       Date:  2004-05       Impact factor: 60.716

2.  Gene therapy finds its niche.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2011-02       Impact factor: 54.908

Review 3.  Trends in risks associated with new drug development: success rates for investigational drugs.

Authors:  J A DiMasi; L Feldman; A Seckler; A Wilson
Journal:  Clin Pharmacol Ther       Date:  2010-02-03       Impact factor: 6.875

4.  Public-private interaction in pharmaceutical research.

Authors:  I Cockburn; R Henderson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

Review 5.  Patterns of technological innovation in biotech.

Authors:  Laura M McNamee; Fred D Ledley
Journal:  Nat Biotechnol       Date:  2012-10       Impact factor: 54.908
  5 in total
  2 in total

1.  What does the current biotech stock market value?

Authors:  Laura McNamee; Fred Ledley
Journal:  Nat Biotechnol       Date:  2015-08       Impact factor: 54.908

2.  Comparing long-term value creation after biotech and non-biotech IPOs, 1997-2016.

Authors:  Ekaterina Galkina Cleary; Laura M McNamee; Skyler de Boer; Jeremy Holden; Liam Fitzgerald; Fred D Ledley
Journal:  PLoS One       Date:  2021-01-06       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.